Pfizer Inc. reported that its fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, yet the world's second-biggest drugmaker topped Wall Street expectations.<br />The New York-based company's revenue rose by 7 percent, ending a long stretch of declining sales due to generic competition to one-time blockbusters.<br />Pfizer benefited from growing sales of its newest products, as well as the additional of injectable medicines made by Hospira, which it acquired last September.<br />The maker of Viagra and pain treatment Lyrica said on Tuesday that net income was $613 million, or 10 cents, per share.<br />A year earlier, its net income was $1.23 billion, or 19 cents per share.
